Discontinued — last reported Q2 '18
Note payable to DIRECTV
Royalty Pharma Note payable to DIRECTV decreased by 67.1% to $17.48M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 6.0%, from $18.60M to $17.48M. Over 5 years (FY 2020 to FY 2025), Note payable to DIRECTV shows a downward trend with a -15.9% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase suggests higher short-term debt reliance, while a decrease indicates the company is successfully paying down specific contractual obligations.
Detailed definition
This represents a short-term financial obligation owed to a specific corporate entity, categorized as a current liabilit...
Peer comparison
Similar to other 'Notes Payable' or 'Accounts Payable to Related Parties' found in the current liabilities section of peer balance sheets.
note_payable_directvHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $117.38M | $119.14M | $107.93M | $116.01M | $115.99M | $105.73M | $12.40M | $98.58M | $0.00 | $0.00 | $11.38M | $9.02M | $97.49M | $31.20M | $68.60M | $18.60M | $3.08M | $3.12M | $53.16M | $17.48M |
| QoQ Change | — | +1.5% | -9.4% | +7.5% | -0.0% | -8.8% | -88.3% | +695.0% | -100.0% | — | — | -20.7% | +981.0% | -68.0% | +119.9% | -72.9% | -83.5% | +1.5% | >999% | -67.1% |
| YoY Change | — | — | — | — | -1.2% | -11.3% | -88.5% | -15.0% | -100.0% | -100.0% | -8.3% | -90.9% | — | — | +503.1% | +106.2% | -96.8% | -90.0% | -22.5% | -6.0% |
Note payable to DIRECTV at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's note payable to directv?
- Royalty Pharma (RPRX) reported note payable to directv of $17.48M in Q1 2026.
- How has Royalty Pharma's note payable to directv changed year-over-year?
- Royalty Pharma's note payable to directv decreased by 6.0% year-over-year, from $18.60M to $17.48M.
- What is the long-term trend for Royalty Pharma's note payable to directv?
- Over 5 years (2020 to 2025), Royalty Pharma's note payable to directv has grown at a -15.9% compound annual growth rate (CAGR), from $126.37M to $53.16M.
- What does note payable to directv mean?
- A short-term debt obligation owed to a specific business partner or related entity.